UPDATE: Credit Suisse Raises PT on Allergan on Compelling Turnaround Story Heading into 2014

Loading...
Loading...
In a report published Thursday, Credit Suisse analyst V. Divan reiterated an Outperform rating on
AllerganAGN
, and raised the price target from $104.00 to $112.00. In the report, Credit Suisse noted, “Increasing conviction on AGN heading into 2014. AGN has been our most debated Outperform pharma call since our initiation. We sense many investors are parked on the sidelines awaiting better clarity on some controversies surrounding the name. Proprietary insights and deep-dive work on these leave us increasingly bullish on the name. We reiterate Outperform and increase TP to $112 (from $104), while increasing EPS estimates for 2014 and beyond.” Allergan closed on Wednesday at $95.65.
Posted In: Analyst ColorPrice TargetAnalyst RatingsCredit SuisseV. Divan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...